Want to see KR:183490 full AI Analyst Report?
Enzychem Lifesciences Corp. (183490) Stock Statistics & Valuation Metrics
Total Valuation
Enzychem Lifesciences Corp. has a market cap or net worth of KRW 76.86B. The enterprise value is -KRW 18.22B.
- Market Cap
- KRW 76.86B
- Enterprise Value
- -KRW 18.22B
Share Statistics
Enzychem Lifesciences Corp. has 84,640,236 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 84,640,236
- Owned by Insiders
- ―
- Owned by Institutions
- 0.51%
Financial Efficiency
Enzychem Lifesciences Corp.’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -9.01%.
- Return on Equity (ROE)
- -0.13
- Return on Assets (ROA)
- -0.12
- Return on Invested Capital (ROIC)
- -9.01%
- Return on Capital Employed (ROCE)
- -0.09
- Revenue Per Employee
- ―
- Profits Per Employee
- ―
- Employee Count
- ―
- Asset Turnover
- 0.46
- Inventory Turnover
- 5.42
Valuation Ratios
The current PE Ratio of Enzychem Lifesciences Corp. is -8.16. Enzychem Lifesciences Corp.’s PEG ratio is -0.77.
- PE Ratio
- -8.16
- PS Ratio
- 0.00
- PB Ratio
- 0.96
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- -16.93
- PEG Ratio
- -0.77
Income Statement
In the last 12 months, Enzychem Lifesciences Corp. had revenue of 67.75B and earned -18.13B in profits. Earnings per share was -234.08.
- Revenue
- 67.75B
- Gross Profit
- 3.38B
- Operating Income
- -13.09B
- Pretax Income
- -18.24B
- Net Income
- -18.13B
- EBITDA
- -14.90B
- Earnings Per Share (EPS)
- -234.08
Cash Flow
In the last 12 months, operating cash flow was -11.01B and capital expenditures -779.47M, giving a free cash flow of -11.79B billion.
- Operating Cash Flow
- -11.01B
- Free Cash Flow
- -11.79B
- Free Cash Flow per Share
- -106.16
Dividends & Yields
Enzychem Lifesciences Corp. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- ―
- Earnings Yield
- -12.28%
Stock Price Statistics
- Beta
- -0.14
- 52-Week Price Change
- -2.37%
- 50-Day Moving Average
- 990.00
- 200-Day Moving Average
- 1025.27
- Relative Strength Index (RSI)
- 37.46
- Average Volume (3m)
- ―
Important Dates
Enzychem Lifesciences Corp. upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Enzychem Lifesciences Corp. as a current ratio of 14.06, with Debt / Equity ratio of 3.52%
- Current Ratio
- 14.06
- Quick Ratio
- 12.62
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- 0.20
- Interest Coverage Ratio
- -64.96
Taxes
In the past 12 months, Enzychem Lifesciences Corp. has paid -147.22M in taxes.
- Income Tax
- -147.22M
- Effective Tax Rate
- 0.01
Enterprise Valuation
Enzychem Lifesciences Corp. EV to EBITDA ratio is 0.27, with an EV/FCF ratio of 0.37.
- EV to Sales
- -0.06
- EV to EBITDA
- 0.27
- EV to Free Cash Flow
- 0.37
- EV to Operating Cash Flow
- 0.38
Balance Sheet
Enzychem Lifesciences Corp. has KRW 92.82B in cash and marketable securities with KRW 4.84B in debt, giving a net cash position of KRW 87.98B billion.
- Cash & Marketable Securities
- KRW 92.82B
- Total Debt
- KRW 4.84B
- Net Cash
- KRW 87.98B
- Net Cash Per Share
- KRW 1,039.48
- Tangible Book Value Per Share
- KRW 1,741.42
Margins
Gross margin is 3.81%, with operating margin of -22.05%, and net profit margin of -34.63%.
- Gross Margin
- 3.81%
- Operating Margin
- -22.05%
- Pretax Margin
- -34.92%
- Net Profit Margin
- -34.63%
- EBITDA Margin
- -23.40%
- EBIT Margin
- -26.58%
Analyst Forecast
The average price target for Enzychem Lifesciences Corp. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -5.10%
- EPS Growth Forecast
- 19.68%
Scores
- Smart Score
- ―
- AI Score
- 49